期刊文献+

文拉法辛对5-羟色胺再回收抑制剂治疗无效的抑郁症疗效观察 被引量:3

下载PDF
导出
摘要 本文用文拉法辛治疗对5-羟色胺再回收抑制剂(SSRI)无效的抑郁症,并对其疗效和安全性进行观察,报告如下。1对象和方法为2008年1月至2010年12月我院符合中国精神障碍分类与诊断标准第3版抑郁发作的诊断标准;汉密尔顿抑郁量表(HAMD-17)评分≥18分;首次治疗采用1种SSRI类抗抑郁药、药量达到最少治疗量、疗程≥6周仍无效(HAMD减分率〈25%)的住院或门诊患者。
出处 《临床精神医学杂志》 2012年第3期161-161,共1页 Journal of Clinical Psychiatry
  • 相关文献

参考文献2

  • 1Baldomero EB, Ubago JG, Cercos CL, et al. Venlafaxine extended release versus conventional antidepressants in the remission of de- pressive disorders after previous antidepressant failure: ARGOS study [ J ]. Depress Anxiety,2005,22 : 68 -76.
  • 2Papakostas GI, Fava M, Thase ME. Treatment of SSRl-resistant de- pression: A recta-analysis comparing within-versus across-class switches[ J]. Biol Psychiatry,2008,63:699-704.

同被引文献37

  • 1中华医学会精神科分会.中国精神障碍分类与诊断标准(第三版)[M].山东:山东科学技术出版社,2002.125-126.
  • 2Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-Ⅳ major depressive episode [ J ]. BMC Med, 2011, 9:90. doi:10.1186/1741-7015-9-90.
  • 3Bauer M, Tharmanathan P, Volz HP, et al. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression : a meta-analysis [ J ]. Eur Arch Psychiatry Clin Neurosci, 2009, 259 ( 3 ) : 172-185. doi : 10. 1007/ s00406-008-0849-0.
  • 4Ingelman-Sundberg M, Sire SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies : pharmacogenetic, pharmacoepigenetic and clinical aspects [ J ]. Pharmacol Ther, 2007, 116 ( 3 ) : 496-526. doi: 10. 1016/j. pharmthera. 2007.09. 004.
  • 5Niwa T, Murayama N, Yamazaki H. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition [ J ]. Curr Drug Metab, 2011, 12 ( 5 ) : 412- 435.
  • 6Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response [ J ]. Mol Psychiatry, 2004, 9 (5) :442-473. doi : 10. 1038/sj. mp. 4001494.
  • 7Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I [ J ]. Clin Pharmacokinet, 2009, 48 ( 11 ) :689-723. doi : 10. 2165/11318030-000000000-00000.
  • 8Nichols AI, Eobello K, Guico-Pabia CJ, et al. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2136 metabolizer status [ J ]. J Clin Psychopharmacol, 2009, 29 ( 4 ) : 383-386. doi : 10. 1097/JCP. 0b013e3181 acc4dd.
  • 9Jiang F, Kim HD, Na HS, et al. The influences of CYP2D6 genotypes and drug interactions on the pharrnacokineties of venlafaxine : exploring predictive biomarkers for treatment outcomes[ J]. Psyehopharmacology (Bed), 2014, [ Epub ahead of prin], doi : 10. 1007/s00213-014-3825-6.
  • 10Preskom SH, Kane CP, Lobello K, et al. Cytochrome P450 2136 phenoconversion is common in patients being treated for depression: implications for personalized medicine [ J ]. J Clin Psychiatry, 2013, 74 (6): 614-621. doi: 10. 4088/JCP. 120107807.

引证文献3

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部